TAK 901

Drug Profile

TAK 901

Alternative Names: TAK-901

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Takeda
  • Developer Millennium; Takeda Oncology
  • Class Amides; Antineoplastics; Heterocyclic bicyclo compounds; Piperidines; Sulfones
  • Mechanism of Action Aurora kinase A inhibitors; Aurora kinase B inhibitors; Aurora kinase C inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Haematological malignancies
  • Discontinued Lymphoma; Solid tumours

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Haematological-malignancies in USA (IV, Infusion)
  • 01 Mar 2013 Millennium completes a phase I trial in Haematological malignancies in USA (NCT00807677)
  • 09 Feb 2012 Phase-I clinical trials in Haematological malignancies in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top